• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
 
  • Détails
Titre

Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.

Type
article
Institution
Externe
Périodique
HPB
Auteur(s)
Hubert, C.
Auteure/Auteur
Sempoux, C.
Auteure/Auteur
Humblet, Y.
Auteure/Auteur
van den Eynde, M.
Auteure/Auteur
Zech, F.
Auteure/Auteur
Leclercq, I.
Auteure/Auteur
Gigot, J.F.
Auteure/Auteur
Liens vers les personnes
Sempoux, Christine  
ISSN
1477-2574
Statut éditorial
Publié
Date de publication
2013
Volume
15
Numéro
11
Première page
858
Dernière page/numéro d’article
864
Langue
anglais
Notes
Publication types: ARTICLE
Résumé
OBJECTIVES: The most frequent presentation of chemotherapy-related toxicity in colorectal liver metastases (CRLM) is sinusoidal obstruction syndrome (SOS). The purpose of the present study was to identify preoperative factors predictive of SOS and to establish associations between type of chemotherapy and severity of SOS. METHODS: A retrospective study was carried out in a tertiary academic referral hospital. Patients suffering from CRLM who had undergone resection of at least one liver segment were included. Grading of SOS on the non-tumoral liver parenchyma was accomplished according to the Rubbia-Brandt criteria. A total of 151 patients were enrolled and divided into four groups according to the severity of SOS (grades 0-3). RESULTS: Multivariate analysis identified oxaliplatin and 5-fluorouracil as chemotherapeutic agents responsible for severe SOS lesions (P < 0.001 and P = 0.005, respectively). Bevacizumab was identified as having a protective effect against the occurrence of SOS lesions (P = 0.005). Univariate analysis identified the score on the aspartate aminotransferase : platelets ratio index (APRI) as the most significant biological factor predictive of severe SOS lesions. Splenomegaly is also significantly associated with the occurrence of severe SOS lesions. CONCLUSIONS: The APRI score and splenomegaly are effective as factors predictive of SOS. Bevacizumab has a protective effect against SOS.
PID Serval
serval:BIB_5C7ECCC7C986
DOI
10.1111/hpb.12047
PMID
23458554
WOS
000325636500005
Permalien
https://iris.unil.ch/handle/iris/94324
Open Access
Oui
Date de création
2015-01-26T10:34:48.007Z
Date de création dans IRIS
2025-05-20T18:07:07Z
  • Copyright © 2024 UNIL
  • Informations légales